Introduction {#S1}
============

Intravenous immunoglobulin {#S1-1}
--------------------------

Intravenous immunoglobulin (IVIg) is prepared from polyclonal immunoglobulin G (IgG) purified from pooled plasma samples of several thousand healthy donors. IgG has been the standard treatment for primary immunodeficiency diseases since Bruton's identification of a patient with agammaglobulinemia in the early 1950s ([@B1]). However, Imbach et al. ([@B2]), in the early 1980s, demonstrated that administration of high doses of human polyclonal IgG in children with immune deficiency who concomitantly suffered from immune thrombocytopenic purpura (ITP) had a dramatic increase in platelet counts. Since then, there has been a progressive increase in the use of IVIg in patients with a wide variety of autoimmune and inflammatory disorders. IVIg is used as a primary treatment for ITP, Kawasaki Syndrome (KS), Guillain--Barré syndrome, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, systemic lupus erythematosus, and other autoimmune and neurologic disorders ([@B3]). IVIg is commonly used in the prevention or treatment of neonatal sepsis. Rationally, those infants who are premature or suffer from very low birth weights should benefit from the immune supplementation provided by IVIg. However, large randomized clinical trials have failed to show consistent benefit in terms of prevention or outcomes from septic episodes ([@B4]--[@B6]). Novel preparations enriched in IgM may have some promise, but to date results are inconsistent ([@B7], [@B8]).

Intravenous immunoglobulin is now the most commonly prescribed plasma-based product worldwide ([@B3], [@B9]). This increased use raises questions regarding the long-term viability of this therapy. Considering the high cost and limited availability of this resource, it is imperative to investigate the underlying mechanisms of IVIg in order to tailor the anti-inflammatory response obtained by treatment, allowing for better therapies for inflammatory and autoimmune diseases. Furthermore, this can lead to the development of non-plasma-derived drugs with similar therapeutic benefits.

Many mechanisms explaining the immune-regulatory actions of IVIg have been postulated, including modulation of inhibitory Fc-gamma receptor (FcγR) expression, blockade of activating FcγR on antigen-presenting cells (APCs), interference with cytokine production, inhibition of cell activation, or induction of apoptosis in a variety of immune cells, including dendritic cells (DCs), macrophages, natural killer (NK) cells, and T and B lymphocytes ([@B3], [@B9], [@B10]). However, a key factor in immune modulation is the ability to counter inflammatory responses with regulatory cells. In this review, we will explore the links between IVIg and regulatory T-cell responses.

Regulatory T cells {#S1-2}
------------------

Regulatory T cells (Treg) were initially described in the 1990s as a specialized subpopulation of T cells that maintain immune system homeostasis and tolerance to self-antigens ([@B11], [@B12]). The transcription factor forkhead box P3 (FOXP3) is considered the marker of choice for this cell ([@B13]). FOXP3 is a master-switch transcription factor: its expression modifies T cells toward a regulatory phenotype, enabling many of the anti-inflammatory functions of Treg ([@B14]). The fundamental property that defines Treg is their ability to transfer immune suppression *in vivo* from one animal to another or *in vitro* from one cell culture to another ([@B15]). Based on their developmental or functional differences, Treg are categorized into two main populations: naturally occurring Treg that are generated in the thymus (tTreg) and peripherally induced Treg (pTreg) generated in peripheral lymphoid tissues from non-Treg precursor CD4^+^ cells. While Treg are CD4^+^ T-effector cells with characteristic FOXP3 expression, this is not sufficient to define a cell population as Treg: single-cell flow cytometric sorting experiments have shown the importance of elevated expression of the high-affinity IL-2 receptor, CD25, as a hallmark of Treg ([@B16]). Other markers, including HLA-DR, GARP, and low CD127 expression, along with CTLA-4 and Helios, are not entirely consistent or reliable and depend on the activation state of the cell ([@B17]). Recent work by Bin Dhuban et al. ([@B18]) has identified two cell-surface Treg markers: TIGIT, a novel CD28-related protein, and FCRL3, an Fc-receptor-like glycoprotein, which allow for high-consistency detection of Treg in human peripheral blood mononuclear cells (PBMCs).

Pre-clinical studies have shown that freshly isolated or *ex vivo-*expanded Treg can confer immunological tolerance in subjects with autoimmune and inflammatory disorders ([@B19], [@B20]). However, human Treg infusion therapy has been difficult to implement, and relatively few clinical trials have been initiated ([@B21]). Therefore, developing new therapeutic approaches with the capability to modulate the immune system through activation and/or expansion of Treg has been the subject of many recent studies. Several therapeutic immunosuppressive compounds, including rapamycin ([@B22]) and glucocorticoids ([@B23]), have been identified as promoting the expansion or suppressive activity of Treg.

Intravenous immunoglobulin has been proposed as a treatment that can promote development or activation of Treg in autoimmune diseases ([@B24]). Herein, we provide an overview examining if IVIg indeed influences induction of Treg in the context of different inflammatory and autoimmune conditions and discuss mechanisms underlying Treg induction by IVIg.

Evidence for the Action of IVIg in the Promotion of Treg in Human Clinical Trials {#S2}
=================================================================================

An early clue suggesting regulatory effects of IVIg was the observation that T cells, purified from IVIg-treated individuals, had significant suppressive effects when cultured with proliferating T and B cells ([@B25]). Subsequent studies demonstrated that IVIg therapy was associated with enhanced mitogen-induced "suppressor T-cell function" in rheumatoid arthritis ([@B26]), ITP ([@B27]), and pediatric acquired immune deficiency syndrome ([@B28]). More recently, Kessel et al. ([@B29]) demonstrated that *in vitro* culture of IVIg with peripheral T cells led to increases in intracellular TGF-β, IL-10, and FOXP3 expression as well as improvement in their suppressive functions when cocultured with effector T cells.

T cells from patients treated with IVIg have been examined for increases in Treg. In Guillain--Barré syndrome, IVIg therapy increases the expression of *FOXP3* and the production of inhibitory cytokines in Treg ([@B30]). In systemic lupus erythematosus, IVIg-treated patients show significant increases in Treg numbers; moreover, IVIg appeared to convert naive FOXP3^−^CD25^−^ into activated FOXP3^+^CD25^+^ Treg ([@B31]). Consistently, IVIg therapy of EGPA patients increased FOXP3^+^ Treg numbers and production of IL-10 in CD4^+^ T cells ([@B32]). In mononeuritis multiplex, a peripheral neuropathy, steroid unresponsive patients treated with IVIg exhibit enhanced populations of Treg ([@B33]).

Mechanisms of action of IVIg in KS {#S2-1}
----------------------------------

Kawasaki syndrome is an acute systemic vascular inflammation, primarily affecting children. A single IVIg treatment is generally successful in reducing fever and associated disease manifestations ([@B34]). Extensive work has focused on characterizing the IVIg-induced Treg response in KS. Burns et al. ([@B35]) investigated the link between TNF-α and IVIg therapy in KS, hypothesizing that TNF-α inhibition may decrease cell activation. They determined that infliximab treatment does not interfere with Treg induction by IVIg, finding that the expansion of CD14^+^ CD86^+^ tolerogenic DC correlated with increased Treg after IVIg treatment. They postulate that the IVIg-induced Treg pool secretes IL-10 and responds to the Ig heavy-chain Fc region.

In a subsequent study from the same group, Franco et al. ([@B36]) investigated the specificity of IVIg-induced Treg in subacute KS patients. IVIg treatment induced a subset of Treg that expressed high levels of CTLA-4, and secreted IL-10, but not TGF-β. This Treg expansion appeared to be key to controlling vascular inflammation in KS. Cloned Treg expanded *ex vivo* only responded to soluble IgG Fc and not to F(ab)′^2^ fragments, indicating that these Treg were Fc-specific and that the mechanism was likely T-cell receptor (TCR)-dependent. Coculture experiments revealed that the Fc region of IgG was presented in a major histocompatibility complex (MHC)-restricted, TCR-mediated manner by EBV-transformed B cells. Further investigation of the Fc peptide specificities of the tTreg population revealed similar profiles in both IVIg-treated KS patients and in healthy controls, suggesting that Treg responses are functionally inadequate in KS and that this can be reversed by IVIg ([@B37]).

In KS patients, IVIg treatment enhances the expression of genes related to Treg activation, including *FOXP3*, *CTLA4*, *GITR*, and *TGFB1*. The expression levels of these genes were significantly lower in KS patients prior to treatment than in healthy controls ([@B38], [@B39]). Ni et al. ([@B40]) examined the mechanisms of Treg dysfunction in KS, focusing on microRNAs (miR). While acute KS patients had lower Treg numbers and decreased Treg marker expression, IVIg treatment increased Treg numbers and *FOXP3*, *CTLA4*, and *GITR* gene expression. Treg from untreated KS have down-regulated miR-155 and miR-21 microRNAs; miR-155 down-regulation leads to increased SOCS1 signaling, decreased STAT-5 signaling, and miR-31 microRNA overexpression. IVIg treatment reversed these effects, restoring the SOCS1/STAT5 balance and decreasing miR-31 expression. FOXP3-dependent miR-155 inhibited SOCS1, and STAT3 suppressed miR-21, which down-regulated FOXP3. IVIg treatment of KS patients lowered elevated IL-6 and pSTAT3, restoring miR-21 levels, providing an explanation for the increase in Treg numbers following IVIg infusion.

Modulatory Effects of IVIg in Animal Models of Inflammatory Disorders via Treg Expansion and Induction {#S3}
======================================================================================================

Role of IVIg in experimental autoimmune encephalomyelitis {#S3-1}
---------------------------------------------------------

In experimental autoimmune encephalomyelitis (EAE), an antigen-driven murine model of multiple sclerosis, IVIg treatment reduced the disease severity scores, promoted the expansion of Treg and enhanced their suppressive capacity, both *in vivo* and *in vitro* ([@B39]). Importantly, administration of IVIg failed to confer protection in EAE mice that were depleted of Treg prior to treatment, suggesting a critical role of endogenous Treg in conferring protection by IVIg. In line with these findings, Okuda et al. ([@B41]) replicated the effects of IVIg in EAE and showed that sulfonated IVIg was effective in increasing the frequency of Treg.

A potential target for IVIg in EAE is NK cells. NK cells have a wide variety of immunomodulatory functions, interacting with B cells, DC, and Treg ([@B42], [@B43]). Chong et al. ([@B44]) hypothesized that in IVIg-treated subjects, NK cells suppress disease by regulating inflammatory T-cell responses. Using an EAE model, they demonstrated that IVIg treatment blocks EAE development and reduces demyelination by diminishing IL-17 and IFN-γ. NK cell depletion by anti-asialo GM1 antibody resulted in the loss of IVIg-mediated protection, and adoptive transfer of IVIg-treated NK cells was as equally protective as IVIg treatment. IVIg-treated NK cells induced CD4^+^ Foxp3^+^ Treg in spleen and draining lymph nodes, which were suppressive to antigen-specific effector T cells in *ex vivo* proliferation assays. Upon further investigation using an *in vitro* coculture system, Treg induction was determined to depend on IL-2 and TGF-β1 production by NK cells. Chong et al. posit that IVIg may promote redistribution of NK cells in peripheral tissues, depending on the inflammatory stimulus. Since NK cells modulate their chemokine receptor expression to facilitate migration to local and peripheral sites of inflammation ([@B45]), IVIg may increase NK cell homing to inflammatory microenvironments and secondary lymphoid organs, where they can induce Treg. NK cell costimulatory molecule expression may also drive Treg induction: IL-2 and plate-bound anti-CD16 treatment up-regulate CD86 and OX-40 ligand on NK cells *in vitro* ([@B46]). CD86 has been implicated in Treg generation ([@B47]), and OX-40 ligand can deliver a survival signal to Treg ([@B48]).

Treg induction in allergen-driven and autoimmune models {#S3-2}
-------------------------------------------------------

We have recently demonstrated, using an ovalbumin-driven murine model of allergic airway disease, that therapeutic administration of IVIg attenuated airway hyper-reactivity (AHR) and alleviated airway inflammation. This was accompanied by induction of highly suppressive, antigen-specific Treg derived from pre-existing T-effector cells. Treg induction was dependent on the interaction of IVIg with CD11c^+^ DC ([@B49]). Similarly, in a murine model of ITP, IVIg increased thymic and splenic Treg, accompanied by restoration of platelet counts ([@B50]).

Different dosing regimens have been used for IVIg to increase Treg ([@B51]). Our laboratory, as well as most other groups, uses high-dose IVIg (2 g/kg), which is analogous to the immunomodulatory dose used in clinical practice ([@B49]). Other studies have used typical antibody-replacement doses of 400--800 mg/kg ([@B52]). Ramakrishna et al. ([@B53]) reported an anti-inflammatory effect using extremely low-dose IVIg (187.5 mg/kg) in a HSV-mediated encephalitis murine model, which was felt to be dependent on enhancement of Treg. This dose range is rarely used clinically, making this work difficult to apply to standard practice. In addition, work from our laboratory and others ([@B38], [@B54]) suggests that a minor fraction of IVIg is required for some, but not all immunomodulatory effects. This will be discussed in more detail below.

Mechanisms of Action of IVIg in Induction of Treg {#S4}
=================================================

The mechanisms by which IVIg induces Treg may involve direct interaction of IgG with T cells, or modulation of other cellular or molecular targets, particularly APCs such as DC and macrophages. IVIg can also interact with other cells, such as B cells or NK cells. In addition, IVIg can modulate the production of proinflammatory cytokines, which may play a role in maintaining T-cell tolerance.

The effect of IVIg on DC activation {#S4-1}
-----------------------------------

Induction of protective T-cell responses requires naive T cells to receive signals via the TCR, costimulatory molecules, and cytokine receptors. These signals, via cell--cell contact and through soluble mediators, are provided by professional APCs, such as DC. While DC represent the most efficient APC in capturing, processing, and presenting antigens to T cells ([@B55]), DC also play an active role in maintaining immune tolerance, as constitutive DC ablation results in spontaneous fatal autoimmunity ([@B56]). Tolerogenic DCs are characterized by decreased expression of costimulatory molecules (CD40, CD80, and CD86), decreased antigen presentation (due to reduced MHC class II expression), enhanced expression of coinhibitory molecules (e.g., PD-L1, CTLA-4, and OX-40), and enhanced inhibitory cytokine production ([@B57], [@B58]). This DC subset is essential for maintaining tolerance via extrathymic induction of pTreg and maintenance of pre-existing tTreg ([@B59]--[@B62]).

Induction of tolerance is critically dependent on the maturation state of DC. An immature DC phenotype is associated with induction, expansion, or enhancement of the suppressive capacity of Treg ([@B63]). Direct cell-to-cell interaction of DC and T cells via TCR ([@B64]), induction of indolamine-2,3-dioxygenase (IDO) ([@B65]), as well as secretion of IL-10, TGF-β, and retinoic acid by DC ([@B66]) are all implicated in the peripheral induction or expansion of Treg by DC.

Although both myeloid and plasmacytoid DC may be involved in maintaining peripheral tolerance ([@B67]), polyclonal human IgG appears to target CD11c^+^ DC rather than CD11c^−^ plasmacytoid DC ([@B49], [@B68]). We have demonstrated that CD11c^+^ DC from IVIg-treated mice are necessary and sufficient for peripheral induction of Treg in lung and draining thoracic lymph nodes ([@B49]). IVIg decreases CD80 and CD86 both *in vitro* and *in vivo*; in addition, adoptively transferred IVIg-treated DC can increase Treg in lungs of antigen-exposed and challenged mice ([@B49], [@B69]).

Intravenous immunoglobulin-exposed CD11c^+^ DCs are less competent in driving lymphocyte proliferation, potentially due to decreased MHC-II and CD80/CD86 expression ([@B68], [@B70]--[@B72]). Work from the group of Bazin suggests that internalized IVIg interferes with antigen presentation by competing with antigen peptides for loading on MHC-II molecules in the intracellular MHC-II compartment (MIIC) ([@B73], [@B74]). Inhibition of T-cell responses by reducing antigen presentation may also interfere with the activation of autoreactive pathogenic T cells. In addition, IVIg alters the pattern of DC cytokine production, including up-regulation of inhibitory cytokines, such as IL-10, and down-regulation of proinflammatory cytokines, such as IL-12 and IFN-γ ([@B53], [@B71], [@B75]).

Proinflammatory cytokines counteract Treg differentiation or decrease Treg suppressive effects. For example, IL-6 secretion from DC is known to abrogate Treg anergy, reverse Treg suppression, and skew Treg differentiation toward Th-17 ([@B76], [@B77]). In contrast, IVIg reduces the production of IL-6 and TNF-α by peripheral blood monocytes ([@B78], [@B79]); it can therefore maintain Treg homeostasis. It is conceivable that IVIg-generated Treg may attenuate DC maturation by anti-inflammatory cytokine production, expanding the inhibitory effects of IVIg by further tolerizing DC in a negative feedback loop.

How IVIg targets DC is still incompletely elucidated, and different mechanisms have been postulated. The effect of polyclonal IgG on DC appears to involve activating FcγR, by triggering immunoreceptor tyrosine-based activation motifs (ITAM) ([@B80]). However, both Fc and F(ab′)^2^ fragments of IgG have been shown to suppress DC maturation and modulate DC cytokine production ([@B71]). F(ab′)^2^ fragments have been shown to inhibit LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK1/2), an intracellular signaling molecule that mediates the inflammatory response induced by Toll-like receptor (TLR) ligation in DC ([@B81]).

Although a full discussion of IVIg-Fcγ receptor biology is beyond the scope of this review, it is important to note that inhibitory FcγRIIB were required for the anti-inflammatory effects of IVIg in murine models of ITP ([@B72]), nephrotoxic nephritis ([@B82]), and epidermolysis bullosa acquisita (EBA) ([@B54]). Similarly, we have found that FcγRIIB is required for IVIg-mediated abrogation of allergic airways disease (Kaufman et al., in preparation). Up-regulation of FcγRIIB expression on DC, and on APC in general, likely plays a role in the suppression of DC activation, although no direct physical interaction between IVIg with this receptor has been reported ([@B83]).

De Groot et al. ([@B84]) proposed another DC-dependent mechanism by which IVIg promotes Treg expansion. They described promiscuous IgG-derived T-cell epitope peptides (Tregitopes) containing epitopes from both Fc and Fab fragments of the IgG molecule, with the capability of activating Foxp3^+^ Treg. They postulated that these Tregitopes are presented in the context of MHC-II by APC to Treg and contribute to Treg activation and expansion ([@B85], [@B86]). This is consistent with the results of Franco et al. ([@B36]) discussed earlier where B cells presented Fc regions of IgG in a MHC-restricted and TCR-mediated manner.

The anti-inflammatory effects of sialylated IgG and its relationship to Treg development {#S4-2}
----------------------------------------------------------------------------------------

Human IgG therapy has two consistently used dosing regimens. Patients requiring immune supplementation for immune deficiency typically receive between 400 and 800 mg/kg monthly. After many years of using lower doses, these were deemed ineffective in crossover studies. Individuals requiring immune modulation frequently receive infusion of IVIg containing two to five times the immune supplementation dose. It has therefore been hypothesized that minor fractions of IVIg provide molecules that supply the anti-inflammatory components needed for immune modulation. This has been demonstrated regarding specific neutralizing antibodies, anti-idiotypic antibodies, or anti-apoptosis antibodies.

The Ravetch group developed the concept that the anti-inflammatory properties of IVIg were isolated to an IgG subset characterized by terminal α-2,6-sialylation of the Fc glycan. Specifically, the Fc portion of the IgG molecule contained an N-linked glycan moiety covalently bound to a highly conserved glycosylation site at Asn297 ([@B87], [@B88]). In various clinical scenarios, lower serum levels of sialylated IgG were found in individuals with systemic lupus erythematosus or juvenile-onset rheumatoid arthritis when compared with healthy controls ([@B89]--[@B91]). This sialylated fraction of IVIg (saIVIg) makes up roughly 1--2% of the total IgG in pooled therapeutic preparations. In proof-of-concept studies, saIVIg was therapeutically effective in animal models of rheumatoid arthritis ([@B92]), ITP ([@B93]), and allergic airways disease ([@B94]) at doses 10 times lower than unfractionated IVIg.

The mechanism of action of saIVIg is still under investigation. Kaneko et al. ([@B87]) proposed that saIVIg interacts with DC-SIGN (DC-specific intercellular adhesion molecule-3 grabbing non-integrin) on human DC or the murine ortholog SIGN-R1 (specific intracellular adhesion molecule-3 grabbing non-integrin homolog-related 1) on murine splenic macrophages. This triggers increased expression of the inhibitory Fc receptor FcγRIIB ([@B88]). This may contribute to the induction and expansion of Treg; FcγRIIB-deficient mice are incapable of generating Treg in a model of mucosal antigen tolerance ([@B95]). Guilliams et al. reviewed the role of FcγRIIB in IVIg therapy and suggested that IVIg increases FcγRIIB expression in inflamed tissues during the effector phase of the immune response ([@B96]).

Using experimental models of multiple sclerosis (EAE) and serum-induced arthritis, Fiebiger et al. ([@B97]) recently reported that saIVIg Fc confers protective effects in T-cell-mediated and antibody-mediated diseases. They developed a mutated IgG Fc construct (F241A), which had a similar structure to saIVIg Fc, but displayed DC-SIGN binding independent of sialylation. Both saIVIg Fc and F241A IgG Fc alleviated arthritis and EAE by inducing Treg expansion and activation, up-regulating FcγRIIB on effector macrophages, and suppressing Th17 and Th1 responses. The anti-inflammatory responses required expression of DC-SIGN as well as secretion of IL-33 by macrophages.

Washburn et al. described a novel hypersialylated IgG derivative, tetra-Fc-sialylated IVIg (s4-IVIg), which was maximally sialylated but lacked advanced glycation end products (AGEs) that are hazardous to human health. s4-IVIg was efficacious in animal models of arthritis, ITP, and EBA ([@B91]). These results substantiate data obtained by Schwab et al. ([@B54]) who demonstrated requirements for IgG sialylation and FcγRIIB expression in their disease models.

As IVIg is a heterogeneous compound, it is not surprising that non-sialylated IgG is also biologically active. Othy et al. demonstrated the effects of IVIg on Th17 and Treg cells independent of Fc sialylation ([@B98]). Similarly, there are studies using different murine models of ITP ([@B99], [@B100]) and rheumatoid arthritis ([@B101]), which did not require sialylated IgG. Differences in strains or induction of pathological conditions in various murine models are reasons for the discrepancies in the dependence on sialylation. To obtain more definitive results, it will be critical to evaluate the role of minor IgG fractions in subjects with inflammatory and autoimmune diseases.

IVIg binds C-type lectin receptors on DCs {#S4-3}
-----------------------------------------

DC-specific intercellular adhesion molecule-3 grabbing non-integrin and SIGN-R1 are C-type lectin receptors, which bind mannosylated and fucosylated structures, such as HIV envelope protein gp120 ([@B102]). While ligation of DC-SIGN by mannose-expressing pathogens stimulates proinflammatory cytokine secretion by DC, fucose-expressing pathogens or synthetic fucose-containing ligands inhibit LPS-induced production of IL-6 and IL-12 and stimulate the secretion of anti-inflammatory IL-10 by DC ([@B103]). Hence, ligation of these innate receptors by saIVIg may regulate cytokine production by DC and therefore contribute to Treg homeostasis. Smits et al. ([@B104]) showed that binding of *Lactobacillus reuteri* and *Lactobacillus casei* bacteria to DC-SIGN on monocyte-derived DC drove the development of Treg. These Treg produced increased levels of IL-10 and were capable of inhibiting the proliferation of bystander T cells in an IL-10-dependent fashion.

Work from the group of Ravetch and other investigators suggests that the conformational changes in IgG molecules induced by sialylation lead to a reduction in binding affinity of IgG to FcγR by masking the FcγR binding site ([@B105]). Furthermore, sialylation exposes a binding site on IgG for carbohydrate-binding C-type lectin receptors such as DC-SIGN or SIGN-R1 ([@B89], [@B97], [@B106]). In contrast, the group of Crispin were unable to reproduce these findings, claiming that sialylation of IgG does not result in conformational changes to the IgG molecule or increases in binding affinity of IgG to DC-SIGN ([@B107], [@B108]). They suggest that cross-linking of sialic-acid-binding Siglecs (sialic acid binding Ig-like lectins), such as CD22, and direct binding of Fc receptors induce inhibitory signaling through immunoreceptor tyrosine-based inhibition motif (ITIM) pathways. We have recently described that IVIg efficiently modifies DCs to induce regulatory T cells in the absence of activating FcγR ([@B94]). It is worth noting that the sialylation of IgG is not restricted to the Fc fragment, and a high proportion of sialic acid residues on the F(ab′)^2^ fragments of IgG has been identified recently by Kasemann et al. ([@B109]).

In addition to DC-SIGN, other C-type lectin receptors may interact with IVIg and contribute to induction and/or expansion of Treg. We have recently reported ([@B94]) that saIVIg specifically interacts with the C-type lectin dendritic cell immunoreceptor (DCIR) on CD11c^+^ DC. This appears to lead to internalization of IgG into DC and is associated with inhibitory signaling in ligated DC that consequently results in the peripheral induction of Foxp3^+^ Treg. The contribution of DCIR^+^ DC in the induction and expansion of Treg has been demonstrated in previous studies, although not in the context of IVIg therapy. Yamazaki et al. ([@B110]) showed that two subsets of CD8^+^CD205^+^ and CD8^−^DCIR^+^ DC differentiate peripheral Foxp3^+^ Treg, in part through the endogenous production of TGF-β. These data indicate that multiple C-lectin receptors are implicated in the generation of tolerogenic DC by IVIg.

Interaction of IVIg with Treg {#S4-4}
-----------------------------

Direct interaction of polyclonal IgG with Treg may represent another mechanism by which IVIg can induce tolerance. Kessel et al. ([@B29]) demonstrated that IVIg increases expression of intracellular FOXP3, TGF-β, and IL-10 when added to culture with human CD4^+^ T cells. IgG was shown to bind to both human and mouse Treg ([@B39], [@B111]), which increased FOXP3 expression, accompanied by augmented *ex vivo* suppressive function. IVIg stimulated phosphorylation of ZAP-70 in Treg ([@B111]), which is known to enhance suppressive activity ([@B112]).

Additionally, interaction of IgG with effector T cells can affect the balance of cytokine production, mainly by down-regulating proinflammatory cytokines, such as IL-2, IFN-γ, and TNF-α, and increasing inhibitory cytokines ([@B113], [@B114]). Early work ([@B115]) on cytokine networks elucidated that IVIg abrogated production of both Th1- and Th2-type proinflammatory cytokines from PBMC in culture. Maddur et al. ([@B116]) demonstrated the reciprocal enhancement of Treg differentiation compared to inhibition of Th17 differentiation in culture, in association with decreases in Th17 effector cytokines (IL-17A, IL-17F, IL-21, and CCL20). In clinical trials, two groups have investigated the effect of IVIg therapy on the profile of intracellular cytokine expression in T cells. In ITP patients who were responsive to IVIg therapy, there was increased production of IL-10 and TGF-β by CD4^+^ T cells as well as decreased Th-1 cytokine production ([@B117], [@B118]).

Experiments from our laboratory could not confirm direct action of IVIg on T cells on the induction of Treg. We examined naive CD4^+^ Foxp3^−^ T cells from Foxp3-GFP reporter mice in the absence of APC. Pre-treatment of these cells with IVIg, followed by coculture with DC and a source of antigen, did not result in the induction of Foxp3 expression, whereas IVIg pretreatment of DC prior to coculture induced Treg *ex vivo*. Further, we found that ([@B49]), in allergic airways disease, Treg induction required CD11c^+^ DC both *in vitro* and *in vivo*, suggesting that the DC compartment is the main target of IVIg in our system. We therefore hypothesize that IVIg first tolerizes DC, which in turn induce Treg.

Modification of chemokine or chemokine receptors on circulating leukocytes is another potential mode of action of IVIg, which would lead to recruitment of cells to specific tissue sites. Evidence suggests that Treg compartmentalization and trafficking are tissue- or organ-specific and that distinct chemokine receptor and integrin expression may contribute to selective trafficking of Treg to inflammatory microenvironments ([@B119]). For instance, expression of chemokine receptors CCR4 and CCR8 are required on Treg for tissue homing ([@B120]). Treg may switch their homing receptor expression profiles depending on the direction of their trafficking. A majority of Treg found in secondary lymphoid tissues express CD62L and CCR7 ([@B121]). Moreover, while both effector and regulatory T cells might express similar patterns of chemokine receptors, both subsets may compete for interaction with APC or access to the site of inflammation.

We have demonstrated in a mouse model of ovalbumin-driven allergic airway disease that IVIg specifically increases the expression of CCR4 on the induced Treg population, suggesting their enhanced ability to recruit to the site of inflammation. Additionally, we found that expression of CD62L, which acts as a homing receptor for lymphocytes entering secondary lymphoid tissues, is decreased in Treg isolated from inflamed lung tissues ([@B49]). In a murine model of ITP, Treg compartmentalization was also modified by IVIg therapy ([@B50]), stressing the potential for action of IVIg on chemokine receptor expression. It is unclear if this action is direct or indirect, via signals from APC.

Conclusion {#S5}
==========

Intravenous immunoglobulin is an extremely complex preparation that contains a multitude of biologically active moieties: it likely achieves immunomodulation through a number of synergistic mechanisms, which provide positive therapeutic effects. The immune-regulatory effects of IVIg appear to be pleiotropic and involve different stages of the inflammatory cascade, with a complex interplay of IgG molecules with different cells and mediators.

In this review, we describe potential mechanisms behind the actions of IVIg in the generation and differentiation of Treg. Recent findings reinforce the efficacy of IVIg in the enhancement of Treg in various autoimmune disorders. The action of IVIg in the modulation of Treg, and the consequent maintenance of immune tolerance, provides a rationale for therapeutic approaches specifically targeting this axis of the immune system. This also renews interest in developing alternative treatments, such as Tregitopes or monoclonal antibodies, for refractory inflammatory and autoimmune diseases, which are often associated with deficiencies in Treg and are difficult to manage with conventional therapeutic approaches.

The effects of IVIg on the potentiation of Treg appear to involve the interaction of IgG with APC and potentially T cells and are dependent on the modulation of cytokine networks within different immune cell types. Based on our own studies and the conclusions of this review, we suggest a set of potential cellular mechanisms, which are summarized schematically in Figure [1](#F1){ref-type="fig"}. Initially, saIVIg binds C-type lectin receptors on DCs (Figure [1](#F1){ref-type="fig"}A), which induces inhibitory FcγRIIB expression on DC or on effector macrophages (Figure [1](#F1){ref-type="fig"}B), thus potentiating the activation threshold of the adaptive arm of the immune system. The associated inhibitory receptor signaling renders the DC tolerogenic, reducing DC costimulatory molecule expression (Figure [1](#F1){ref-type="fig"}C) and proinflammatory cytokine secretion (Figure [1](#F1){ref-type="fig"}D). Anti-inflammatory cytokine and mediator production by both DC and Treg (Figure [1](#F1){ref-type="fig"}E) and presentation of IgG regulatory epitopes (Figure [1](#F1){ref-type="fig"}F) to Treg by DC decrease proinflammatory cytokine production in naive effector T cells (Figure [1](#F1){ref-type="fig"}G) and generate Treg from non-Treg precursors (Figure [1](#F1){ref-type="fig"}H). These Treg inhibit effector Th1, Th2, and Th17 cell proliferation and activity (Figure [1](#F1){ref-type="fig"}I) in the inflammatory microenvironment and secrete anti-inflammatory cytokines (Figure [1](#F1){ref-type="fig"}E) that tolerize DC. In addition, IVIg-mediated modulation of chemokine or chemokine receptor expression in T-cell subsets might contribute to the homeostasis or regulation of trafficking of Treg, although proper functional characterization is needed. NK cells play a role in processing of innate antigens and have multiple known ITIM-linked receptors: IVIg may target NK cells to directly induce Treg by cytokine production or cell--cell contact (discussed earlier). IVIg-treated NK cells may also induce antibody-dependent cellular cytotoxicity of mature DC, which reduces antigen presentation and inhibits proinflammatory effector T-cell function ([@B122]).

![**IVIg tolerizes DC, which interacts with T cells to induce Treg**. Sialylated IVIg ligates C-type lectin receptors on DC **(A)**, which induces FcγRIIB expression **(B)** and reduces costimulatory molecule expression **(C)** and proinflammatory cytokine secretion **(D)**. Anti-inflammatory cytokine and mediator production **(E)** and presentation of IgG regulatory epitopes **(F)** decrease proinflammatory cytokine production in naive effector T cells **(G)** and generate Treg from non-Treg precursors **(H)**. These Treg inhibit effector Th1, Th2, and Th17 cell proliferation and activity **(I)** in the inflammatory microenvironment and secrete anti-inflammatory cytokines **(E)** that tolerize DC. CLRs, C-type lectin receptors; GITR, glucocorticoid-induced TNFR family related gene; ITIM, immunoreceptor tyrosine-based inhibition motif; RA, retinoic acid.](fimmu-06-00469-g001){#F1}

Interaction of sialylated IgG with C-type lectin receptors triggers an inhibitory response in ligated cells that might consequently provide the required signals for maintaining immune tolerance. In this review, we bring evidence that shows the association of this interaction with the promotion of Treg. However, more investigation is still required to elucidate the beneficial effects of IVIg in modulation of Treg, particularly in clinical trials. Further avenues of research include identifying specific cellular markers or phenotypic patterns associated with DC tolerogenicity as well as precise characterization of the IVIg-generated Treg population.
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